0001493152-26-009667
SEC filingNutra Pharma Corp. reported a net loss of $1.4 million for Q1 2025, driven by a $1.0 million non-cash change in the fair value of convertible notes and derivatives, which contributed to total other expenses of -$1.1 million. The company generated $74K in net sales, with $36K coming from a related party, resulting in a gross profit of $68K. Operating loss was -$350K, primarily due to selling, general and administrative expenses of $418K. Cash flow from operations was -$405K, while financing activities provided $408K, mainly from $424K in proceeds from convertible notes. The balance sheet shows total assets of $775K, total liabilities of $17.0 million, and a stockholders' deficit of -$16.2 million, indicating significant financial leverage. No prior period QoQ comparisons are provided in the filing.
Nutra Pharma Corp. reported a net loss of $1.4 million for the first quarter ending March 31, 2025. The loss was primarily driven by a $1.0 million non-cash charge for the change in fair value of convertible notes and derivatives, which contributed to total other expenses of -$1.1 million. The company generated $74K in net sales, with $36K (49%) coming from a related party. Gross profit was $68K, but operating expenses of $418K resulted in an operating loss of -$350K. No prior period QoQ comparisons are provided in the filing, limiting trend analysis.
The filing does not provide segment breakdowns, geographic mix, or detailed growth drivers beyond the total net sales figure of $74K. The document indicates $36K of net sales were to a related party, representing 49% of total revenue. No further revenue diversification or product line details are disclosed in the provided data.
Gross margin was 91.9%, calculated from $68K gross profit on $74K net sales. However, operating margin was -472.97% due to the operating loss of -$350K relative to the small revenue base. The cost structure shows selling, general and administrative expenses of $418K significantly outweighing gross profit. No prior period margin comparisons are available in the filing.
Operating activities used $405K in cash, while investing activities used $26K for property and equipment purchases. Financing activities provided $408K, primarily from $424K in proceeds from convertible notes. The balance sheet shows total assets of $775K, with current assets of $552K including $14K in cash. Total liabilities are $17.0 million, including $16.8 million in current liabilities, resulting in a stockholders' deficit of -$16.2 million and negative working capital.
The filing does not contain management guidance, strategic priorities, or specific risk factor discussions in the provided content. No forward-looking statements or outlook information is included in the extracted financial data and document text.